º£½ÇÉçÇø

º£½ÇÉçÇø — LOS ANGELES (Jan. 29, 2025) --  is partnering with Oxford Science Enterprises (OSE), through a major co-investment initiative. The partnership with OSE, an independent investment company launched as a joint venture with the University of Oxford, will include the ability to co-build and co-invest in future health-tech startups coming out of Oxford.

To initiate the ongoing collaboration, Cedars-Sinai Intellectual Property Company and OSE have invested $2 million in , a startup from the University of Oxford. The London-based organization offers a digital smartphone-based neurology-care platform to improve outcomes for Parkinson’s disease and dementia patients. This investment follows Neu Health’s participation in Cedars-Sinai’s 10th  program last year.

“The research produced at Oxford is of the highest caliber,” said , executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai. “We are delighted to further pursue this ongoing relationship with OSE, which will serve our patients and strengthen the academic and clinical missions of Cedars-Sinai.”

The Neu Health platform, backed by more than a decade of research and clinical validation by University of Oxford, includes a patient app linked to a care team dashboard. The platform uses unique data and artificial intelligence to translate motor and non-motor symptoms as well as cognitive and mental health abilities into objective, actionable information for clinicians. With increasing usage in the United Kingdom, the company will pilot its digital platform at Cedars-Sinai to expand and enter the United States market. The first 150 neurology patients are expected to start using the Neu Health app soon as part of the six-month pilot program.

“We are excited to strengthen our relationship with Cedars-Sinai, given our shared commitment to commercializing world-leading research and building innovative businesses,” said Heather Roxborough, PhD, senior partner of Health Tech at Oxford Science Enterprises. “This partnership plays a critical role in accelerating our entry into the United States market, providing our companies access to invaluable commercial and clinical insights and the opportunity to test our healthcare technologies.”

Through the strategic partnership, the two respected organizations aim to foster the growth of innovative health-tech startups, expand U.S. and U.K. market reach and plan future alliances on both sides of the Atlantic.  

"Investing in the research and technology coming out of Oxford through our partnership with Oxford Science Enterprises is the beginning of what we hope will become a long and fruitful relationship," said , chief executive of Cedars-Sinai Intellectual Property Company. "Together, we can work on furthering Cedars-Sinai’s mission of providing patients around the world the best care possible.”

Read more on the Cedars-Sinai Blog: